E-resources
Peer reviewed
Open access
-
Saavedra, Cristina; Gion, María; Cortés, Javier; Llombart‐Cussac, Antonio
Cancer, 15 June 2023, Volume: 129, Issue: 12Journal Article
Although breast cancer has led the way toward precision medicine, more research is still needed to increase curation rates in patients with early disease and to prolong survival with an optimal quality of life in the metastatic setting. Last year, big advances were achieved toward these goals thanks to the significant impact of immunotherapy on survival in triple‐negative breast cancer and the exciting results of antibody‐drug conjugates. Plain Language Summary The development of new drugs and biomarkers to select those patients who will benefit of them are crucial in improving survival in breast cancer. Last year, the emergence of antibody‐drug conjugates and the reaffirmation of the potential of immunotherapy in breast cancer were the most important findings. The definitive establishment of immunotherapy in triple‐negative breast cancer and the amazing results of the new antibody‐drug conjugates are the main landmarks in 2021 and 2022, and constitute the beginning of a new era in the treatment of breast cancer.
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.